Kur­ma scores $175M in first clos­ing of biotech/healthtech fund — the VC's largest yet

French VC Kur­ma has been in­vest­ing in­to sev­er­al com­pa­nies re­cent­ly, such as AR­M­GO Phar­ma and Emer­gence Ther­a­peu­tics. With its new biotech and healthtech-fo­cused fund, the VC is now look­ing to ex­pand its of­fer­ings in pos­si­bly its biggest fund to date.

The VC said this morn­ing that the fund, dubbed the Growth Op­por­tu­ni­ties Fund, hit its first clos­ing, se­cur­ing just shy of $175 mil­lion from dif­fer­ent in­vestors. But the firm has a high­er goal: €250 mil­lion, or $273 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER